Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab

Andreas Seeber, Ioana Braicu, Gerold Untergasser, Mani Nassir, Dominic Fong, Laura Botta, Guenther Gastl, Heidi Fiegl, Alain Zeimet, Jalid Sehouli, Gilbert Spizzo

Open source

DOI: 10.18632/oncotarget.4496
Published: 2015-07-10
Container: Oncotarget
Publisher: Impact Journals, LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.18632/oncotarget.4496,
  title = {Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab},
  author = {Andreas Seeber and Ioana Braicu and Gerold Untergasser and Mani Nassir and Dominic Fong and Laura Botta and Guenther Gastl and Heidi Fiegl and Alain Zeimet and Jalid Sehouli and Gilbert Spizzo},
  year = {2015},
  journal = {Oncotarget},
  doi = {10.18632/oncotarget.4496},
  url = {https://doi.org/10.18632/oncotarget.4496}
}

RIS

TY  - JOUR
TI  - Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
AU  - Andreas Seeber
AU  - Ioana Braicu
AU  - Gerold Untergasser
AU  - Mani Nassir
AU  - Dominic Fong
AU  - Laura Botta
AU  - Guenther Gastl
AU  - Heidi Fiegl
AU  - Alain Zeimet
AU  - Jalid Sehouli
AU  - Gilbert Spizzo
PY  - 2015
JO  - Oncotarget
DO  - 10.18632/oncotarget.4496
UR  - https://doi.org/10.18632/oncotarget.4496
ER  -

APA

Seeber, A., Braicu, I., Untergasser, G., Nassir, M., Fong, D., Botta, L., Gastl, G., Fiegl, H., Zeimet, A., Sehouli, J., & Spizzo, G. (2015). Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. Oncotarget. https://doi.org/10.18632/oncotarget.4496

Source records

crossref · retrieved 2026-09-26T12:41:22.486Z